KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Net Cash Flow: 2014-2025

Historic Net Cash Flow for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Sep 2025 value amounting to $20.2 million.

  • Aurinia Pharmaceuticals' Net Cash Flow rose 440.48% to $20.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.0 million, marking a year-over-year increase of 489.49%. This contributed to the annual value of $34.6 million for FY2024, which is 176.29% up from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Net Cash Flow stood at $20.2 million for Q3 2025, which was up 250.36% from -$13.4 million recorded in Q2 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' Net Cash Flow peaked at $174.3 million during Q4 2021, and registered a low of -$115.8 million during Q1 2021.
  • In the last 3 years, Aurinia Pharmaceuticals' Net Cash Flow had a median value of -$5.2 million in 2023 and averaged -$1.9 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first slumped by 491.42% in 2021, then spiked by 1,768.08% in 2024.
  • Over the past 5 years, Aurinia Pharmaceuticals' Net Cash Flow (Quarterly) stood at $174.3 million in 2021, then crashed by 95.34% to $8.1 million in 2022, then plummeted by 69.48% to $2.5 million in 2023, then spiked by 1,768.08% to $46.3 million in 2024, then surged by 440.48% to $20.2 million in 2025.
  • Its Net Cash Flow was $20.2 million in Q3 2025, compared to -$13.4 million in Q2 2025 and -$17.0 million in Q1 2025.